FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117546979> ?p ?o ?g. }

• W2117546979 endingPage "1265" @default.
• W2117546979 startingPage "1261" @default.
• W2117546979 abstract "BackgroundWe hypothesized that, among molecular subclasses of breast cancer, p53 status may have a differential predictive value for the efficacy of anthracyclines/alkylating agents-based regimen. We analysed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification.Patients and methodsOestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) expression and p53 status were determined by immunohistochemistry in 293 samples from two different centres. A logistic regression model was used for multivariate analysis of predictors for pathological complete response (pCR).Resultsp53 immunostaining (54%) was associated with high grade (P = 0.002) and ER negativity (P = 0.04). p53 was detected in 59% of triple-negative tumours (ER-/PgR-/HER2-, n = 120 patients). In the overall population, pCR (9.6%) was independently predicted by high tumour grade (P = 0.002) and ER/PgR/HER2 triple negativity (P = 0.0004), but not by p53 status (P = 0.12). p53 immunostaining was associated with a trend for a higher rate of pCR in triple-negative tumours [relative risk (RR) = 2.5, 95% confidence interval (CI) = 0.8–7.5, P = 0.09], but not in non-triple-negative tumours (RR = 0.73, 95% CI = 0.16–3.3, P = 0.69).Conclusionp53 status may have a different predictive value for efficacy of anthracycline/alkylating agents-based regimen in each molecular subclass, a result which may explain the different results reported in literature." @default.
• W2117546979 created "2016-06-24" @default.
• W2117546979 creator A5001814176 @default.
• W2117546979 creator A5005415404 @default.
• W2117546979 creator A5016200153 @default.
• W2117546979 creator A5029086962 @default.
• W2117546979 creator A5049799682 @default.
• W2117546979 creator A5061340891 @default.
• W2117546979 creator A5072115990 @default.
• W2117546979 creator A5072502548 @default.
• W2117546979 creator A5083142899 @default.
• W2117546979 creator A5084500159 @default.
• W2117546979 date "2008-07-01" @default.
• W2117546979 modified "2023-10-05" @default.
• W2117546979 title "p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes" @default.
• W2117546979 cites W1769240683 @default.
• W2117546979 cites W1961026612 @default.
• W2117546979 cites W1977131634 @default.
• W2117546979 cites W1978224665 @default.
• W2117546979 cites W1978331365 @default.
• W2117546979 cites W1982097971 @default.
• W2117546979 cites W2000557631 @default.
• W2117546979 cites W2002259547 @default.
• W2117546979 cites W2022289852 @default.
• W2117546979 cites W2041594739 @default.
• W2117546979 cites W2047179113 @default.
• W2117546979 cites W2063669247 @default.
• W2117546979 cites W2066882336 @default.
• W2117546979 cites W2071106257 @default.
• W2117546979 cites W2099335989 @default.
• W2117546979 cites W2104528117 @default.
• W2117546979 cites W2110426068 @default.
• W2117546979 cites W2114473143 @default.
• W2117546979 cites W2131994307 @default.
• W2117546979 cites W2141572172 @default.
• W2117546979 cites W2141719586 @default.
• W2117546979 cites W2145539398 @default.
• W2117546979 cites W2154142993 @default.
• W2117546979 cites W4294413353 @default.
• W2117546979 cites W4298797619 @default.
• W2117546979 doi "https://doi.org/10.1093/annonc/mdn039" @default.
• W2117546979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18325917" @default.
• W2117546979 hasPublicationYear "2008" @default.
• W2117546979 type Work @default.
• W2117546979 sameAs 2117546979 @default.
• W2117546979 citedByCount "56" @default.
• W2117546979 countsByYear W21175469792012 @default.
• W2117546979 countsByYear W21175469792013 @default.
• W2117546979 countsByYear W21175469792014 @default.
• W2117546979 countsByYear W21175469792015 @default.
• W2117546979 countsByYear W21175469792016 @default.
• W2117546979 countsByYear W21175469792018 @default.
• W2117546979 countsByYear W21175469792019 @default.
• W2117546979 countsByYear W21175469792020 @default.
• W2117546979 countsByYear W21175469792021 @default.
• W2117546979 countsByYear W21175469792022 @default.
• W2117546979 countsByYear W21175469792023 @default.
• W2117546979 crossrefType "journal-article" @default.
• W2117546979 hasAuthorship W2117546979A5001814176 @default.
• W2117546979 hasAuthorship W2117546979A5005415404 @default.
• W2117546979 hasAuthorship W2117546979A5016200153 @default.
• W2117546979 hasAuthorship W2117546979A5029086962 @default.
• W2117546979 hasAuthorship W2117546979A5049799682 @default.
• W2117546979 hasAuthorship W2117546979A5061340891 @default.
• W2117546979 hasAuthorship W2117546979A5072115990 @default.
• W2117546979 hasAuthorship W2117546979A5072502548 @default.
• W2117546979 hasAuthorship W2117546979A5083142899 @default.
• W2117546979 hasAuthorship W2117546979A5084500159 @default.
• W2117546979 hasBestOaLocation W21175469791 @default.
• W2117546979 hasConcept C121608353 @default.
• W2117546979 hasConcept C126322002 @default.
• W2117546979 hasConcept C143998085 @default.
• W2117546979 hasConcept C204232928 @default.
• W2117546979 hasConcept C2776802502 @default.
• W2117546979 hasConcept C2780110267 @default.
• W2117546979 hasConcept C2781413609 @default.
• W2117546979 hasConcept C2908647359 @default.
• W2117546979 hasConcept C4224716 @default.
• W2117546979 hasConcept C530470458 @default.
• W2117546979 hasConcept C71924100 @default.
• W2117546979 hasConcept C84606932 @default.
• W2117546979 hasConcept C98717036 @default.
• W2117546979 hasConcept C99454951 @default.
• W2117546979 hasConceptScore W2117546979C121608353 @default.
• W2117546979 hasConceptScore W2117546979C126322002 @default.
• W2117546979 hasConceptScore W2117546979C143998085 @default.
• W2117546979 hasConceptScore W2117546979C204232928 @default.
• W2117546979 hasConceptScore W2117546979C2776802502 @default.
• W2117546979 hasConceptScore W2117546979C2780110267 @default.
• W2117546979 hasConceptScore W2117546979C2781413609 @default.
• W2117546979 hasConceptScore W2117546979C2908647359 @default.
• W2117546979 hasConceptScore W2117546979C4224716 @default.
• W2117546979 hasConceptScore W2117546979C530470458 @default.
• W2117546979 hasConceptScore W2117546979C71924100 @default.
• W2117546979 hasConceptScore W2117546979C84606932 @default.
• W2117546979 hasConceptScore W2117546979C98717036 @default.
• W2117546979 hasConceptScore W2117546979C99454951 @default.
• W2117546979 hasIssue "7" @default.

• next